Fortunately, Gemigliptin, a novel DPP‐4 inhibitor, could efficiently inhibit LECT2 expressions, improve hepatic steatosis and ameliorate insulin resistance by increasing AMPK phosphorylation and reducing CD209 receptor‐mediated JNK pathway. Here, LECT2 is linked to fatty liver disease.